Fremanezumab
Summary
Risk. As a monoclonal antibody, fremanezumab is not expected to pose a risk to the environment as it is metabolised to aminoacids.
This summary information is derived from the assessment report.
Detailed information
Assessment report
Assessment report for Ajovy (fremanezumab) 31 January 2019 EMA/118499/2019.
"Ecotoxicity/environmental risk assessment of fremanezumab was not conducted. As a monoclonal antibody, fremanezumab is not expected to pose a risk to the environment as it is metabolised to aminoacids."
Author: Health and Medical Care Administration, Region Stockholm